MedTrace Logo

ONO-4538 Study in Patients With Advanced Non-Small Cell Lung Cancer

NCT02175017 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 104

Last updated 2024-12-09

Study results available
· View outcomes & findings →

Summary

The objective of the study is to investigate the efficacy and safety of ONO-4538 in subjects with stage IIIB/IV or recurrent non-small cell lung cancer unsuited to radical radiotherapy and resistant to a platinum-based chemotherapeutic regimen.

Conditions

  • Advanced Non-small Cell Lung Cancer (NSCLC)

Interventions

DRUG

ONO-4538

ONO-4538 Study in Patients With Squamous NSCLC

DRUG

ONO-4538

ONO-4538 Study in Patients With Non-Squamous NSCLC

Sponsors & Collaborators

  • Ono Pharmaceutical Co. Ltd

    lead INDUSTRY

Principal Investigators

  • Mitsunobu Tanimoto · Ono Pharmaceutical Co. Ltd

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-06-30
Primary Completion
2015-11-30
Completion
2021-02-28

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02175017 on ClinicalTrials.gov